Oxygenta Pharma

Why is Oxygenta Pharmaceutical Ltd falling/rising?

As of 10-Jun, Oxygenta Pharmaceutical Ltd's stock price is at Rs 48.41, reflecting a 2.2% decrease and underperforming against the Sensex. The stock has seen a total drop of 4% over the past two days, is trading below all major moving averages, and has experienced a significant decline in investor participation.

As of 10-Jun, Oxygenta Pharmaceutical Ltd's stock price is falling, currently at Rs 48.41, which reflects a decrease of Rs 1.09 or 2.2%. The stock has been underperforming relative to the benchmark Sensex, with a performance today that is 2.13% lower than its sector. It has experienced consecutive declines over the past two days, totaling a 4% drop in returns during this period. <BR><BR>Additionally, the stock opened with a loss of 2% today and reached an intraday low of Rs 48.04, marking a decrease of 2.95%. Oxygenta Pharmaceutical is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Furthermore, there has been a significant drop in investor participation, with delivery volume on June 9 falling by 49.72% compared to the 5-day average. This decline in trading activity suggests reduced interest from investors, contributing to the downward pressure on the stock price. Overall, these factors collectively indicate why Oxygenta Pharmaceutical Ltd is experiencing a decline in its stock price.

What does Oxygenta Pharma do?

Oxygenta Pharmaceutical Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, recently reporting net sales of 50 Cr and a net loss of 2 Cr for March 2026. The company was renamed from S S Organics Limited in FY 2021-22 and has a market cap of INR 179 Cr.

Overview:<BR>Oxygenta Pharmaceutical Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was initially incorporated in 1990 as S S Organics Private Limited, converted to a Public Limited Company in 1993 under the name S S Organics Limited, and was renamed Oxygenta Pharmaceutical Limited in FY 2021-22. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 50 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 179 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -2.52 <BR>Return on Equity: 41.16% <BR>Price to Book: -4.29 <BR><BR>Contact Details:<BR>Address: Survey No 252/1 Aroor Village, Sadasivapet Mandal Medak Telangana : 502291 <BR>Tel: 91-08455-250080/250280 <BR>Email: info@ssorganics.co.in <BR>Website: http://oxygentapharma.com

Which are the latest news on Oxygenta Pharma?

How big is Oxygenta Pharma?

As of 10th June, Oxygenta Pharmaceutical Ltd has a market capitalization of 179.00 Cr and reported net sales of 112.97 Cr with a net loss of 17.58 Cr over the latest four quarters.

As of 10th June, Oxygenta Pharmaceutical Ltd has a market capitalization of 179.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Oxygenta reported net sales of 112.97 Cr. However, the company experienced a net loss of 17.58 Cr during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's funds stood at a loss of 25.02 Cr, while total assets were valued at 72.62 Cr.

Who are in the management team of Oxygenta Pharma?

The management team of Oxygenta Pharma includes Sai Sudhakar Vankineni (Managing Director), D Vidya Sagar, Muralidhar R, Sangari Kondal Reddy, Padmaja Surapureddy (Independent Directors), Kanuganti Raghavender Rao (Executive Director), Sravani Reddy Gantla, Bharath Reddy Guntuku (Additional Directors), and Dolly Mandhan (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of Oxygenta Pharma includes the following members:<BR><BR>1. **Sai Sudhakar Vankineni** - Managing Director<BR>2. **D Vidya Sagar** - Independent Director<BR>3. **Muralidhar R** - Director (Technical)<BR>4. **Sangari Kondal Reddy** - Independent Director<BR>5. **Padmaja Surapureddy** - Independent Director<BR>6. **Kanuganti Raghavender Rao** - Executive Director<BR>7. **Sravani Reddy Gantla** - Additional Director<BR>8. **Bharath Reddy Guntuku** - Additional Director<BR>9. **Dolly Mandhan** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Should I buy, sell or hold Oxygenta Pharmaceutical Ltd?

When is the next results date for Oxygenta Pharmaceutical Ltd?

The next results date for Oxygenta Pharmaceutical Ltd is 23 May 2026.

The next results date for Oxygenta Pharmaceutical Ltd is scheduled for 23 May 2026.

Are Oxygenta Pharmaceutical Ltd latest results good or bad?

Oxygenta Pharmaceutical Ltd's latest results show a significant revenue increase of 137.27% to ₹33.93 crores, but the company reported an operating loss of ₹4.08 crores and a net loss of ₹4.84 crores, indicating ongoing financial distress and operational challenges. Overall, the results are not good, raising concerns for investors.

Oxygenta Pharmaceutical Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. On one hand, the company reported a significant revenue increase of 137.27% quarter-on-quarter, reaching ₹33.93 crores. However, this impressive top-line growth did not translate into profitability. The company faced an operating loss of ₹4.08 crores, resulting in a negative operating margin of 12.02%. <BR><BR>Moreover, the net loss for the quarter was ₹4.84 crores, which is a 23.16% decline compared to the same quarter last year. The persistent negative book value of ₹-6.77 per share and ongoing operational inefficiencies raise serious concerns about the company's financial health and long-term viability. <BR><BR>In summary, while the revenue growth is noteworthy, the underlying operational challenges and continued losses indicate that the overall results are not good. The company is facing significant financial distress, which warrants caution for investors.

How has been the historical performance of Oxygenta Pharma?

Oxygenta Pharma experienced significant sales growth, reaching 109.30 Cr in March 2025, but faced rising expenditures leading to negative operating profit of -10.00 Cr and worsening profitability metrics. Total liabilities increased to 72.62 Cr, with negative shareholder's funds at -25.02 Cr, indicating ongoing financial distress despite a slight improvement in cash flow from operations.

Answer:<BR>The historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from operating activities showed a slight improvement to 2.00 Cr in March 2025, compared to -13.00 Cr in March 2024, but cash flow from investing activities was negative at -11.00 Cr.<BR><BR>Breakdown:<BR>Oxygenta Pharma's financial trajectory reflects a complex mix of growth and challenges. The company's net sales surged to 109.30 Cr in March 2025, a significant increase from previous years, yet this growth was overshadowed by a sharp rise in total expenditure, which reached 119.30 Cr, resulting in an operating profit of -10.00 Cr. This trend continued with a profit before tax of -14.35 Cr and a profit after tax of -10.30 Cr, indicating deteriorating profitability. The total liabilities climbed to 72.62 Cr, with total debt at 62.23 Cr, while shareholder's funds remained negative at -25.02 Cr, highlighting ongoing financial difficulties. Despite a positive cash flow from operating activities of 2.00 Cr, the overall financial health of Oxygenta Pharma appears precarious as it navigates through these challenges.

Who are the top shareholders of the Oxygenta Pharma?

The top shareholders of Oxygenta Pharma are M V S Prasad Reddy with 25.56%, and Sravani Reddy Gantla as the highest public shareholder at 12.13%. Individual investors own 43.93%, with no pledged promoter holdings or foreign institutional investors involved.

The top shareholders of Oxygenta Pharma include M V S Prasad Reddy, who holds the largest stake at 25.56%. The highest public shareholder is Sravani Reddy Gantla, with a holding of 12.13%. Additionally, individual investors collectively own 43.93% of the company. There are no pledged promoter holdings, and the company does not have any foreign institutional investors (FIIs) involved.

Is Oxygenta Pharma overvalued or undervalued?

As of June 20, 2023, Oxygenta Pharma is considered overvalued and risky due to its negative financial ratios, including a PE ratio of -45.92 and a ROCE of -32.27%, despite a strong stock performance of 284.59% over the past year.

As of 20 June 2023, Oxygenta Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued, given its negative PE ratio of -45.92, an EV to EBITDA ratio of -52.33, and a ROCE of -32.27%. These ratios suggest that the company's earnings and capital efficiency are under severe pressure.<BR><BR>In comparison to its peers, Oxygenta Pharma's valuation metrics are starkly unfavorable. For instance, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25, while Cipla Ltd. boasts a PE of 22.99, both indicating a healthier financial position. Additionally, Oxygenta's PEG ratio stands at 0.00, which is significantly lower than the industry averages. Despite its recent stock performance, which has outpaced the Sensex with a 1-year return of 284.59% versus 7.60%, the underlying financial ratios suggest that the stock is not supported by fundamental value, reinforcing the conclusion that it is overvalued.

What is the technical trend for Oxygenta Pharma?

As of May 12, 2025, Oxygenta Pharma's trend has shifted to bullish, supported by positive weekly MACD and KST indicators, although caution is advised due to a bearish monthly RSI, despite a strong 1Y return of 274.62%.

As of 12 May 2025, the technical trend for Oxygenta Pharma has changed from mildly bullish to bullish. The weekly MACD and KST are both bullish, supporting the bullish stance. The daily moving averages also indicate a bullish trend. However, the monthly RSI is bearish, which suggests some caution. Overall, the strength of the bullish trend is reinforced by the performance metrics, with significant returns over various periods, particularly the 1Y return of 274.62%.

Has Oxygenta Pharma declared dividend?

No Dividend History Available

Who are the peers of the Oxygenta Pharma?

Oxygenta Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Oxygenta Pharma has a 1-year return of 169.57%, its peers show varying management risks and growth rates, with Divi's Lab having the highest return at 51.96%.

Peers: The peers of Oxygenta Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Trident Lifeline, Gennex Lab., Sanjiv.Parant., Ambalal Sarabhai, and Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Sanjiv.Parant., while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted for Gennex Lab. and Ambalal Sarabhai, while Average management risk is seen at Trident Lifeline and Sat Kartar. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Trident Lifeline, and Sat Kartar, while Below Average growth is noted for Divi's Lab. and Torrent Pharma, and the rest. Oxygenta Pharma does not qualify for any ratings in Management Risk, Growth, or Capital Structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Gennex Lab. at -22.86%. Oxygenta Pharma's 1-year return of 169.57% significantly exceeds both. Additionally, Gennex Lab. and Ambalal Sarabhai have negative six-month returns.